JP2017500372A - 出血または凝固性低下と関係する容態の治療療法または予防療法 - Google Patents
出血または凝固性低下と関係する容態の治療療法または予防療法 Download PDFInfo
- Publication number
- JP2017500372A JP2017500372A JP2016552450A JP2016552450A JP2017500372A JP 2017500372 A JP2017500372 A JP 2017500372A JP 2016552450 A JP2016552450 A JP 2016552450A JP 2016552450 A JP2016552450 A JP 2016552450A JP 2017500372 A JP2017500372 A JP 2017500372A
- Authority
- JP
- Japan
- Prior art keywords
- fva
- bleeding
- apc
- super
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361899544P | 2013-11-04 | 2013-11-04 | |
US61/899,544 | 2013-11-04 | ||
US201461944915P | 2014-02-26 | 2014-02-26 | |
US61/944,915 | 2014-02-26 | ||
PCT/US2014/063898 WO2015066700A2 (en) | 2013-11-04 | 2014-11-04 | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017500372A true JP2017500372A (ja) | 2017-01-05 |
Family
ID=53005421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016552450A Pending JP2017500372A (ja) | 2013-11-04 | 2014-11-04 | 出血または凝固性低下と関係する容態の治療療法または予防療法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10407488B2 (pt) |
EP (1) | EP3065768B1 (pt) |
JP (1) | JP2017500372A (pt) |
KR (1) | KR20160070163A (pt) |
CN (1) | CN105848668A (pt) |
BR (1) | BR112016009954A2 (pt) |
CA (1) | CA2929671A1 (pt) |
WO (1) | WO2015066700A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2959277T3 (es) * | 2016-05-13 | 2024-02-22 | Scripps Research Inst | Composiciones y métodos para terapias antitrombóticas y hemostáticas |
MX2019002510A (es) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
CN109260462B (zh) * | 2018-08-24 | 2021-05-11 | 上海交通大学医学院附属瑞金医院 | 一种凝血酶原突变体蛋白及其编码核酸的应用 |
CN109316599A (zh) * | 2018-08-24 | 2019-02-12 | 上海交通大学医学院附属瑞金医院 | 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用 |
JP2022515770A (ja) | 2018-12-21 | 2022-02-22 | カイマブ・リミテッド | 共通の軽鎖を有するFIXa×FX二重特異性抗体 |
JP2022524291A (ja) * | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えVWF(rVWF)を使用する予防治療法 |
US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
JP2023526880A (ja) * | 2020-05-26 | 2023-06-26 | ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク-ウニヴェルシテート・マインツ | コロナウイルス感染症および関連する凝固障害を処置するための方法および組成物 |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
US20240075001A1 (en) * | 2022-05-24 | 2024-03-07 | Darren Rubin | Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients |
CN116426510B (zh) * | 2023-06-13 | 2023-09-22 | 北京沃森赛瑟生物技术有限公司 | 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
DE4416166C2 (de) | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
EP2110385A1 (en) * | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
BR0213953A (pt) * | 2001-11-09 | 2004-08-31 | Novo Nordisk Healthcare Ag | Composição farmacêutica, kit de partes, uso de fator vii ou um polipeptìdeo relacionado com fator vii em combinação com um fator v ou um polipeptìdeo relacionado com fator v, uso de uma composição, métodos para tratar episódios de sangramento em um sujeito, para reduzir o tempo de coagulação, para intensificar hemóstase, para prolongar o tempo de lise de coágulos em um sujeito, e para incrementar a resistência do coágulo em um sujeito, kit contendo um tratamento para episódios de sangramento |
US7125846B2 (en) | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
WO2008059041A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
CN101969984A (zh) | 2007-12-20 | 2011-02-09 | 昆士兰大学 | 调节止血的组合物及其用途 |
WO2010149172A2 (en) * | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
-
2014
- 2014-11-04 BR BR112016009954A patent/BR112016009954A2/pt not_active IP Right Cessation
- 2014-11-04 KR KR1020167014735A patent/KR20160070163A/ko not_active Application Discontinuation
- 2014-11-04 CA CA2929671A patent/CA2929671A1/en not_active Abandoned
- 2014-11-04 JP JP2016552450A patent/JP2017500372A/ja active Pending
- 2014-11-04 EP EP14856815.7A patent/EP3065768B1/en active Active
- 2014-11-04 US US15/034,385 patent/US10407488B2/en active Active
- 2014-11-04 WO PCT/US2014/063898 patent/WO2015066700A2/en active Application Filing
- 2014-11-04 CN CN201480067132.4A patent/CN105848668A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3065768B1 (en) | 2020-09-23 |
US10407488B2 (en) | 2019-09-10 |
WO2015066700A2 (en) | 2015-05-07 |
US20160289299A1 (en) | 2016-10-06 |
EP3065768A4 (en) | 2017-07-19 |
EP3065768A2 (en) | 2016-09-14 |
CA2929671A1 (en) | 2015-05-07 |
BR112016009954A2 (pt) | 2017-12-05 |
CN105848668A (zh) | 2016-08-10 |
WO2015066700A3 (en) | 2015-07-16 |
KR20160070163A (ko) | 2016-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017500372A (ja) | 出血または凝固性低下と関係する容態の治療療法または予防療法 | |
CA2690218C (en) | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders | |
US7425539B2 (en) | Factor IXa for the treatment of bleeding disorders | |
KR101567762B1 (ko) | Fvⅲ 농축물을 포함하는 프로트롬빈 복합체 농축물의 상승적 치료 용도 | |
JP2017114889A (ja) | 再構成後の精製第viii因子の安定性を改善するための方法 | |
US20050181978A1 (en) | Therapeutic use of factor XI | |
EP0977584B1 (en) | PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE | |
Sim et al. | In vitro characterization of CT‐001—a short‐acting factor VIIa with enhanced prohemostatic activity | |
CA2540986A1 (en) | Therapeutic use of factor xi | |
KR102658958B1 (ko) | 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품 | |
EP1240901A1 (en) | Medicinal compositions for treating and preventing diseases based on abnormal blood coagulation | |
KR102597725B1 (ko) | 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법 | |
AU2015245941A1 (en) | Half-life extended Factor FVIIa protein for prevention and treatment of bleeding and dosing regimens therefor | |
KR20020092469A (ko) | 인자 VIIa 및 인자 XIII를 포함하는 제약학적조성물 | |
MXPA06005477A (en) | Therapeutic use of factor xi |